We are analyzing https://link.springer.com/article/10.1007/s10557-007-6030-6.

Title:
Myocardial Ischaemia-reperfusion Injury is Attenuated by Intact Glucagon Like Peptide-1 (GLP-1) in the In Vitro Rat Heart and may Involve the p70s6K Pathway | Cardiovascular Drugs and Therapy
Description:
Background and methods Glucagon Like Peptide-1 (GLP-1), one of the most potent incretin hormones, has potential beneficial actions on the ischaemic and failing heart. This study sought to further identify the mechanisms of action of GLP-1 on the ischaemic heart using an in vitro isolated perfused rat heart model of ischaemic-reperfusion injury (measuring infarct size to area of risk (%)) subjected to 35 min regional ischaemia and 2 h reperfusion. To examine the effect of intact GLP-1 we used an inhibitor of GLP-1 breakdown, Valine pyrrolidide (VP). The downstream target of phosphatidylinositol 3-kinase includes the mTOR/p70s6 kinase pathway which was pharmacologically inhibited by rapamycin. Results and conclusion GLP-1 alone did not decrease myocardial infarction (54.4 ± 3.1%). VP alone did not decrease myocardial infarction (52.5 ± 4%). GLP-1 in the presence of VP produced significant reduction in myocardial infarction compared to control hearts (28.4 ± 2.7% vs. 56.4 ± 3.9% vs. P < 0.05). Inhibiting p70s6 Kinase with rapamycin completely abolished GLP-1 induced protection (57.1 ± 4.9% vs. 28.4 ± 2.7% P < 0.05). There was no detectable increase in the phosphorylated p70s6k after either 5 or 10 min of treatment with GLP-1/VP or with VP alone in comparison to control blots. In conclusion we show for the first time that the protective effects of GLP-1 are mediated by intact GLP-1 and can be inhibited by blocking the p70s6 kinase.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Insurance

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,016 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

article, glp, cas, google, scholar, pubmed, peptide, myocardial, heart, glucagonlike, injury, kinase, signalling, rat, infarction, privacy, cookies, content, glucagon, bose, yellon, reperfusion, access, publish, search, ischaemiareperfusion, intact, vitro, psk, mocanu, carr, rapamycin, data, protection, information, log, journal, research, drugs, pathway, amal, ischaemic, effects, discover, res, cell, circ, download, author, springer,

Topics {✒️}

matrix-assisted laser desorption/ionization-time month download article/chapter pro-apoptotic molecule bad myocardial ischaemia-reperfusion injury glucose-dependent insulinotropic polypeptide article cardiovascular drugs rapamycin induced inhibition related subjects full article pdf mtor/p70s6 kinase pathway dipeptidyl peptidase iv ischaemia/reperfusion injury ischaemia-reperfusion injury cell signalling privacy choices/manage cookies ischaemic-reperfusion injury decrease myocardial infarction myocardial infarction compared myocardial infarction complicated acute myocardial infarction inhibiting p70s6 kinase potential beneficial actions left ventricular dysfunction phosphatidylinositol 3-kinase includes vitro rat heart potent incretin hormones measuring infarct size flight mass spectrometry raf/mek/erk article bose 35 min regional ischaemia conditions privacy policy peptide-1 increases camp accepting optional cookies european economic area ischemic porcine myocardium article log p70s6k pathway published main content log cardiogenic shock myocardial protection article cite check access instant access journal finder publish author correspondence p70s6 kinase rat glucagon data protection therapy aims

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Myocardial Ischaemia-reperfusion Injury is Attenuated by Intact Glucagon Like Peptide-1 (GLP-1) in the In Vitro Rat Heart and may Involve the p70s6K Pathway
         description:Glucagon Like Peptide-1 (GLP-1), one of the most potent incretin hormones, has potential beneficial actions on the ischaemic and failing heart. This study sought to further identify the mechanisms of action of GLP-1 on the ischaemic heart using an in vitro isolated perfused rat heart model of ischaemic-reperfusion injury (measuring infarct size to area of risk (%)) subjected to 35 min regional ischaemia and 2 h reperfusion. To examine the effect of intact GLP-1 we used an inhibitor of GLP-1 breakdown, Valine pyrrolidide (VP). The downstream target of phosphatidylinositol 3-kinase includes the mTOR/p70s6 kinase pathway which was pharmacologically inhibited by rapamycin. GLP-1 alone did not decrease myocardial infarction (54.4 ± 3.1%). VP alone did not decrease myocardial infarction (52.5 ± 4%). GLP-1 in the presence of VP produced significant reduction in myocardial infarction compared to control hearts (28.4 ± 2.7% vs. 56.4 ± 3.9% vs. P < 0.05). Inhibiting p70s6 Kinase with rapamycin completely abolished GLP-1 induced protection (57.1 ± 4.9% vs. 28.4 ± 2.7% P < 0.05). There was no detectable increase in the phosphorylated p70s6k after either 5 or 10 min of treatment with GLP-1/VP or with VP alone in comparison to control blots. In conclusion we show for the first time that the protective effects of GLP-1 are mediated by intact GLP-1 and can be inhibited by blocking the p70s6 kinase.
         datePublished:2007-05-31T00:00:00Z
         dateModified:2007-05-31T00:00:00Z
         pageStart:253
         pageEnd:256
         sameAs:https://doi.org/10.1007/s10557-007-6030-6
         keywords:
            glucagon like peptide-1
            ischaemic preconditioning
            rapamycin
            reperfusion injury
            Cardiology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-007-6030-6/MediaObjects/10557_2007_6030_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-007-6030-6/MediaObjects/10557_2007_6030_Fig2_HTML.gif
         isPartOf:
            name:Cardiovascular Drugs and Therapy
            issn:
               1573-7241
               0920-3206
            volumeNumber:21
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Amal K. Bose
               affiliation:
                     name:University College London Hospital & Medical School
                     address:
                        name:The Hatter Institute and Centre for Cardiology, University College London Hospital & Medical School, London, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Mihaela M. Mocanu
               affiliation:
                     name:University College London Hospital & Medical School
                     address:
                        name:The Hatter Institute and Centre for Cardiology, University College London Hospital & Medical School, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Richard D. Carr
               affiliation:
                     name:NovoNordisk A/S, Novo Allé
                     address:
                        name:NovoNordisk A/S, Novo Allé, Bagsvaerd, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Derek M. Yellon
               affiliation:
                     name:University College London Hospital & Medical School
                     address:
                        name:The Hatter Institute and Centre for Cardiology, University College London Hospital & Medical School, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Myocardial Ischaemia-reperfusion Injury is Attenuated by Intact Glucagon Like Peptide-1 (GLP-1) in the In Vitro Rat Heart and may Involve the p70s6K Pathway
      description:Glucagon Like Peptide-1 (GLP-1), one of the most potent incretin hormones, has potential beneficial actions on the ischaemic and failing heart. This study sought to further identify the mechanisms of action of GLP-1 on the ischaemic heart using an in vitro isolated perfused rat heart model of ischaemic-reperfusion injury (measuring infarct size to area of risk (%)) subjected to 35 min regional ischaemia and 2 h reperfusion. To examine the effect of intact GLP-1 we used an inhibitor of GLP-1 breakdown, Valine pyrrolidide (VP). The downstream target of phosphatidylinositol 3-kinase includes the mTOR/p70s6 kinase pathway which was pharmacologically inhibited by rapamycin. GLP-1 alone did not decrease myocardial infarction (54.4 ± 3.1%). VP alone did not decrease myocardial infarction (52.5 ± 4%). GLP-1 in the presence of VP produced significant reduction in myocardial infarction compared to control hearts (28.4 ± 2.7% vs. 56.4 ± 3.9% vs. P < 0.05). Inhibiting p70s6 Kinase with rapamycin completely abolished GLP-1 induced protection (57.1 ± 4.9% vs. 28.4 ± 2.7% P < 0.05). There was no detectable increase in the phosphorylated p70s6k after either 5 or 10 min of treatment with GLP-1/VP or with VP alone in comparison to control blots. In conclusion we show for the first time that the protective effects of GLP-1 are mediated by intact GLP-1 and can be inhibited by blocking the p70s6 kinase.
      datePublished:2007-05-31T00:00:00Z
      dateModified:2007-05-31T00:00:00Z
      pageStart:253
      pageEnd:256
      sameAs:https://doi.org/10.1007/s10557-007-6030-6
      keywords:
         glucagon like peptide-1
         ischaemic preconditioning
         rapamycin
         reperfusion injury
         Cardiology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-007-6030-6/MediaObjects/10557_2007_6030_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-007-6030-6/MediaObjects/10557_2007_6030_Fig2_HTML.gif
      isPartOf:
         name:Cardiovascular Drugs and Therapy
         issn:
            1573-7241
            0920-3206
         volumeNumber:21
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Amal K. Bose
            affiliation:
                  name:University College London Hospital & Medical School
                  address:
                     name:The Hatter Institute and Centre for Cardiology, University College London Hospital & Medical School, London, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Mihaela M. Mocanu
            affiliation:
                  name:University College London Hospital & Medical School
                  address:
                     name:The Hatter Institute and Centre for Cardiology, University College London Hospital & Medical School, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Richard D. Carr
            affiliation:
                  name:NovoNordisk A/S, Novo Allé
                  address:
                     name:NovoNordisk A/S, Novo Allé, Bagsvaerd, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Derek M. Yellon
            affiliation:
                  name:University College London Hospital & Medical School
                  address:
                     name:The Hatter Institute and Centre for Cardiology, University College London Hospital & Medical School, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cardiovascular Drugs and Therapy
      issn:
         1573-7241
         0920-3206
      volumeNumber:21
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University College London Hospital & Medical School
      address:
         name:The Hatter Institute and Centre for Cardiology, University College London Hospital & Medical School, London, UK
         type:PostalAddress
      name:University College London Hospital & Medical School
      address:
         name:The Hatter Institute and Centre for Cardiology, University College London Hospital & Medical School, London, UK
         type:PostalAddress
      name:NovoNordisk A/S, Novo Allé
      address:
         name:NovoNordisk A/S, Novo Allé, Bagsvaerd, Denmark
         type:PostalAddress
      name:University College London Hospital & Medical School
      address:
         name:The Hatter Institute and Centre for Cardiology, University College London Hospital & Medical School, London, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Amal K. Bose
      affiliation:
            name:University College London Hospital & Medical School
            address:
               name:The Hatter Institute and Centre for Cardiology, University College London Hospital & Medical School, London, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Mihaela M. Mocanu
      affiliation:
            name:University College London Hospital & Medical School
            address:
               name:The Hatter Institute and Centre for Cardiology, University College London Hospital & Medical School, London, UK
               type:PostalAddress
            type:Organization
      name:Richard D. Carr
      affiliation:
            name:NovoNordisk A/S, Novo Allé
            address:
               name:NovoNordisk A/S, Novo Allé, Bagsvaerd, Denmark
               type:PostalAddress
            type:Organization
      name:Derek M. Yellon
      affiliation:
            name:University College London Hospital & Medical School
            address:
               name:The Hatter Institute and Centre for Cardiology, University College London Hospital & Medical School, London, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:The Hatter Institute and Centre for Cardiology, University College London Hospital & Medical School, London, UK
      name:The Hatter Institute and Centre for Cardiology, University College London Hospital & Medical School, London, UK
      name:NovoNordisk A/S, Novo Allé, Bagsvaerd, Denmark
      name:The Hatter Institute and Centre for Cardiology, University College London Hospital & Medical School, London, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(71)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.6s.

LINK . SPRINGER . COM {}